0000310764-17-000161.txt : 20171026 0000310764-17-000161.hdr.sgml : 20171026 20171026160417 ACCESSION NUMBER: 0000310764-17-000161 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20171026 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20171026 DATE AS OF CHANGE: 20171026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STRYKER CORP CENTRAL INDEX KEY: 0000310764 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 381239739 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-09165 FILM NUMBER: 171156327 BUSINESS ADDRESS: STREET 1: 2825 AIRVIEW BLVD CITY: KALAMAZOO STATE: MI ZIP: 49002 BUSINESS PHONE: 2693892600 MAIL ADDRESS: STREET 1: 2825 AIRVIEW BLVD CITY: KALAMAZOO STATE: MI ZIP: 49002 8-K 1 syk8k102617.htm 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 26, 2017
 
strykerlogoa31.jpg

STRYKER CORPORATION
(Exact name of registrant as specified in its charter)
Michigan
(State or other jurisdiction
of incorporation)
000-9165
(Commission
File Number)
38-1239739
(IRS Employer
Identification No.)
 
 
 
2825 Airview Boulevard, Kalamazoo, Michigan
(Address of principal executive offices)
49002
(Zip Code)
 
 
 
Registrant's telephone number, including area code: 269.385.2600

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    [ ]




ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Stryker Corporation issued a press release on October 26, 2017 announcing its third quarter 2017 operating results. A copy of this press release is attached hereto as Exhibit 99.1.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits
 
 
 
 
 
 
Press release dated:
October 26, 2017

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
STRYKER CORPORATION
 
(Registrant)
 
 
 
 
October 26, 2017
/s/ GLENN S. BOEHNLEIN
Date
Glenn S. Boehnlein
 
Vice President, Chief Financial Officer



 EX-99.1 2 sykex991earningsreleas102617.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1

STRYKER REPORTS THIRD QUARTER 2017 RESULTS
Kalamazoo, Michigan - October 26, 2017 - Stryker Corporation (NYSE:SYK) reported operating results for the third quarter of 2017:
Third Quarter Highlights
Net sales grew 6.1% to $3.0 billion (5.8% constant currency)
    
Orthopaedics
5.1
%
or
4.8
%
constant currency
MedSurg
6.7
%
or
6.2
%
constant currency
Neurotechnology and Spine
6.9
%
or
7.0
%
constant currency
Reported net earnings per diluted share increased 21.3% to $1.14
Adjusted net earnings per diluted share(1) increased 9.4% to $1.52
"We delivered strong growth despite headwinds related to Sage products and hurricanes, which is reflected in our revised sales and earnings outlook," said Kevin A. Lobo, Chairman and Chief Executive Officer. "Our teams continue to execute well, and we are also pleased to have closed on the NOVADAQ acquisition in the quarter."

Sales Analysis
Consolidated net sales of $3.0 billion increased 6.1% in the quarter as reported and 5.8% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.3%. Excluding the 0.3% impact of acquisitions, net sales in the quarter increased 5.5% in constant currency including 6.5% from increased unit volume (including negative impacts of 1.8% related to Sage product recalls and temporary ship holds and 0.6% related to hurricanes) partially offset by 1.0% due to lower prices.
Orthopaedics net sales of $1.1 billion increased 5.1% in the quarter as reported and 4.8% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.3%. Excluding the 0.3% impact of acquisitions, net sales in the quarter increased 4.5% in constant currency, including 6.5% from increased unit volume (including negative impacts of 0.4% related to hurricanes) partially offset by 2.0% due to lower prices.
MedSurg net sales of $1.3 billion increased 6.7% in the quarter as reported and 6.2% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.5%. Excluding the 0.6% impact of acquisitions, net sales in the quarter increased 5.6% in constant currency, including 5.6% increased unit volume (including negative impacts of 4.6% related to Sage product recalls and ship holds and 0.8% related to hurricanes). The impact of acquisitions is primarily attributed to NOVADAQ Technologies Inc. (NOVADAQ), the previously announced acquisition that was completed during the quarter. NOVADAQ is now part of Endoscopy.
Neurotechnology and Spine net sales of $0.5 billion increased 6.9% in the quarter as reported and 7.0% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.1%. Net sales in the quarter increased 8.1% from increased unit volume (including negative impacts of 0.5% related to hurricanes) partially offset by 1.1% due to lower prices.
Earnings Analysis
Reported net earnings of $434 million increased 22.3% in the quarter. Reported net earnings per diluted share of $1.14 increased 21.3% in the quarter. Reported net earnings includes certain charges for the amortization of purchased intangible assets, product recalls, restructuring-related activities, and acquisition and integration related activities. The effect of each of these matters on reported net earnings and net earnings per diluted share appears in the reconciliation of actual results to adjusted results below. Excluding the impact of these items increases gross profit margin in the quarter from 65.9% to 66.0% and increases operating income margin from 17.4% to 24.2%. Excluding the impact of the items described above, adjusted net earnings(2) of $578 million increased 9.9% in the quarter. Adjusted net earnings per diluted share(1) of $1.52 increased 9.4% in the quarter.
During the quarter, we initiated a voluntary product recall involving specific lots of our Sage Products (Sage) Oral Care products. We took this action in response to a Warning Letter received from the U.S. Food and Drug Administration (FDA) dated July 17, 2017, which set forth concerns regarding the potential for cross-contamination of Oral Care solutions manufactured by a third party supplier on equipment also used to manufacture non-pharmaceutical products.  We discontinued business with the third-party supplier and the Oral Care solutions are now being manufactured in-house by Sage. We resumed shipping Oral Care products in October and continue to anticipate a return to full supply capacity by year-end.
We also placed Sage cloth-based products on a temporary ship hold during the quarter in response to concerns set forth in the FDA Warning Letter regarding testing methods used for all Sage products containing solutions.  We resumed shipping products manufactured by Sage and tested under the testing method required by FDA in September and continue to anticipate a return to full supply capacity by year-end.
These matters, along with recent hurricanes and the NOVADAQ acquisition, had a negative impact on adjusted net earnings per diluted share in the quarter of approximately $0.05.
2017 Outlook
Based on our year-to-date performance, we now expect 2017 organic net sales growth to be in the range of 6.5% to 7.0% and expect adjusted net earnings per diluted share(3) to be in the range of $6.45 to $6.50. For the fourth quarter we expect adjusted net earnings per diluted share to be in the range of $1.92 to $1.97. If foreign currency exchange rates hold near current levels, we expect net sales in the fourth quarter will be impacted positively by approximately 1.0%, the full year to be nominally impacted and adjusted net earnings per diluted share to be negatively impacted by approximately $0.02 in the fourth quarter and $0.10 in the full year.

1

(1) A reconciliation of reported net earnings per diluted share to adjusted net earnings per diluted share, a non-GAAP financial measure, and other important information appears below.
(2) A reconciliation of reported net earnings to adjusted net earnings, a non-GAAP financial measure, and other important information appears below. 
(3) A reconciliation of expected net earnings per diluted share to expected adjusted net earnings per diluted share for the fourth quarter and full year and other important information appears below.

Conference Call on Thursday, October 26, 2017
As previously announced, the Company will host a conference call on Thursday, October 26, 2017 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended September 30, 2017 and provide an operational update.
To participate in the conference call dial (844) 826-0610 (domestic) or (973) 453-3249 (international) and be prepared to provide conference ID number 77238428 to the operator.
A simultaneous webcast of the call will be accessible via the Company's website at www.stryker.com. The call will be archived on the Investor Relations page of this site.
A recording of the call will also be available from 8:00 p.m., Eastern Time, on Thursday, October 26, 2017, until 11:59 p.m., Eastern Time, on Thursday, November 2, 2017. To hear this recording you may dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and enter conference ID number 77238428.
Caution Concerning Forward-Looking Statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.
For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com
For media inquiries please contact:
Yin Becker, Stryker Corporation, 269-385-2600 or yin.becker@stryker.com


2


STRYKER CORPORATION
For the Three and Nine Months September 30
(Unaudited - Millions of Dollars, Except Per Share Amounts)
CONDENSED STATEMENTS OF EARNINGS
 
Three Months
 
Nine Months
 
2017
 
2016
 
% Change
 
2017
 
2016
 
% Change
Net sales
$
3,006

 
$
2,833

 
6.1
 %
 
$
8,973

 
$
8,168

 
9.9
 %
Cost of sales
1,024

 
960

 
6.7

 
3,039

 
2,759

 
10.1

Gross profit
$
1,982

 
$
1,873

 
5.8
 %
 
$
5,934

 
$
5,409

 
9.7
 %
% of sales
65.9
%
 
66.1
%
 
 
 
66.1
%
 
66.2
%
 
 
Research, development and engineering expenses
198

 
184

 
7.6

 
582

 
526

 
10.6

Selling, general and administrative expenses
1,103

 
1,057

 
4.4

 
3,335

 
3,044

 
9.6

Recall charges
66

 
57

 
15.8

 
164

 
104

 
57.7

Amortization of intangible assets
92

 
89

 
3.4

 
275

 
230

 
19.6

Total operating expenses
$
1,459

 
$
1,387

 
5.2
 %
 
$
4,356

 
$
3,904

 
11.6
 %
Operating income
$
523

 
$
486

 
7.6
 %
 
$
1,578

 
$
1,505

 
4.9
 %
% of sales
17.4
%
 
17.2
%
 
 
 
17.6
%
 
18.4
%
 
 
Other income (expense), net
(52
)
 
(67
)
 
(22.4
)
 
(164
)
 
(172
)
 
(4.7
)
Earnings before income taxes
$
471

 
$
419

 
12.4
 %
 
$
1,414

 
$
1,333

 
6.1
 %
Income taxes
37

 
64

 
(42.2
)
 
145

 
196

 
(26.0
)
Net earnings
$
434

 
$
355

 
22.3
 %
 
$
1,269

 
$
1,137

 
11.6
 %
Net earnings per share of common stock:
 
 
 
 
 
 
 
 
 
 
 
Basic
$
1.16

 
$
0.95

 
22.1
 %
 
$
3.39

 
$
3.04

 
11.5
 %
Diluted
$
1.14

 
$
0.94

 
21.3
 %
 
$
3.34

 
$
3.01

 
11.0
 %
Weighted-average shares outstanding - in millions:
 
 
 
 
 
 
 
 
 
 
 
Basic
374.2

 
374.4

 
 
 
373.8

 
373.9

 
 
Diluted
380.2

 
379.0

 
 
 
379.8

 
378.3

 
 
CONDENSED BALANCE SHEETS
 
September
 
December
 
2017
 
2016
Assets
 
 
 
Cash and cash equivalents
$
2,592

 
$
3,316

Marketable securities
97

 
68

Accounts receivable, net
1,965

 
1,967

Inventories
2,454

 
2,030

Other current assets
602

 
480

Total current assets
$
7,710

 
$
7,861

Property, plant and equipment, net
1,852

 
1,569

Goodwill and other intangibles, net
10,496

 
9,864

Other noncurrent assets
1,427

 
1,141

Total assets
$
21,485

 
$
20,435

Liabilities and shareholders' equity
 
 
 
Current liabilities
$
3,021

 
$
2,554

Accrued recall expenses
237

 
594

Other noncurrent liabilities
1,209

 
1,051

Long-term debt, excluding current maturities
6,593

 
6,686

Shareholders' equity
10,425

 
9,550

Total liabilities and shareholders' equity
$
21,485

 
$
20,435

CONDENSED STATEMENTS OF CASH FLOWS
 
Nine Months
 
2017
 
2016
Operating activities
 
 
 
Net earnings
$
1,269

 
$
1,137

Depreciation
198

 
165

Amortization of intangible assets
275

 
230

Changes in operating assets and liabilities and other, net
(862
)
 
(275
)
Net cash provided by operating activities
$
880

 
$
1,257

Investing activities
 
 
 
Acquisitions, net of cash acquired
$
(712
)
 
$
(4,296
)
Change in marketable securities, net
(29
)
 
633

Purchases of property, plant and equipment
(412
)
 
(347
)
Other investing, net
—

 
(4
)
Net cash used in investing activities
$
(1,153
)
 
$
(4,014
)
Financing activities
 
 
 
Borrowings/repayments of debt, net
$
300

 
$
2,818

Dividends paid
(477
)
 
(426
)
Repurchases of common stock
(230
)
 
(13
)
Other financing
(115
)
 
(69
)
Net cash (used in) provided by financing activities
$
(522
)
 
$
2,310

Effect of exchange rate changes on cash and cash equivalents
71

 
21

Change in cash and cash equivalents
$
(724
)
 
$
(426
)

3

STRYKER CORPORATION
For the Three and Nine Months September 30
(Unaudited - Millions of Dollars)
CONDENSED SALES ANALYSIS
 
Three Months
 
Nine Months
 
 
Percentage Change
 
 
Percentage Change
 
2017
2016
As Reported
Constant
Currency
 
2017
2016
As Reported
Constant
Currency
Geographic:
 
 
 
 
 
 
 
 
 
United States
$
2,182

$
2,059

6.0
%
6.0
%
 
$
6,546

$
5,930

10.4
%
10.4
%
International
824

774

6.4

5.4

 
2,427

2,238

8.5

9.6

Total
$
3,006

$
2,833

6.1
%
5.8
%
 
$
8,973

$
8,168

9.9
%
10.2
%
Segment:
 
 
 
 
 
 
 
 
 
Orthopaedics
$
1,132

$
1,077

5.1
%
4.8
%
 
$
3,408

$
3,216

6.0
%
6.4
%
MedSurg
1,336

1,253

6.7

6.2

 
3,977

3,469

14.7

14.9

Neurotechnology and Spine
538

503

6.9

7.0

 
1,588

1,483

7.0

7.5

Total
$
3,006

$
2,833

6.1
%
5.8
%
 
$
8,973

$
8,168

9.9
%
10.2
%
SUPPLEMENTAL SALES GROWTH ANALYSIS
 
Three Months
 
 
Percentage Change
 
 
 
 
United States
International
 
2017
2016
As Reported
Constant Currency
As Reported
As Reported
Constant Currency
Orthopaedics:
 
 
 
 
 
 
 
Knees
$
369

$
354

4.2
 %
3.9
 %
4.3
 %
4.0
 %
2.6
 %
Hips
313

310

1.0

0.9

0.2

2.2

1.9

Trauma and Extremities
367

343

7.4

6.9

11.2

1.0

(0.2
)
Other
83

70

16.3

15.9

20.4

0.7

(1.0
)
Total Orthopaedics
$
1,132

$
1,077

5.1
 %
4.8
 %
6.5
 %
2.2
 %
1.2
 %
MedSurg:
 
 
 
 
 
 
 
Instruments
$
404

$
380

6.3
 %
6.1
 %
6.4
 %
6.1
 %
4.8
 %
Endoscopy
404

364

10.9

10.4

13.8

1.7

(0.4
)
Medical
464

450

3.4

2.8

(1.0
)
21.5

18.5

Sustainability
64

59

7.3

7.3

7.1

57.3

53.0

Total MedSurg
$
1,336

$
1,253

6.7
 %
6.2
 %
5.8
 %
9.9
 %
7.7
 %
Neurotechnology and Spine:
 
 
 
 
 
 
 
Neurotechnology
$
353

$
311

13.5
 %
13.7
 %
11.8
 %
16.6
 %
17.1
 %
Spine
185

192

(3.7
)
(3.8
)
(3.6
)
(4.2
)
(4.3
)
Total Neurotechnology and Spine
$
538

$
503

6.9
 %
7.0
 %
5.3
 %
10.3
 %
10.7
 %
Total
$
3,006

$
2,833

6.1
 %
5.8
 %
6.0
 %
6.4
 %
5.4
 %
 
Nine Months
 
 
Percentage Change
 
 
 
 
United States
International
 
2017
2016
As Reported
Constant Currency
As Reported
As Reported
Constant Currency
Orthopaedics:
 
 
 
 
 
 
 
Knees
$
1,149

$
1,085

5.9
 %
6.2
 %
6.3
 %
5.0
 %
5.9
 %
Hips
955

949

0.6

1.3

1.5

(0.8
)
1.0

Trauma and Extremities
1,070

998

7.3

7.7

10.9

1.4

2.5

Other
234

184

26.6

26.5

26.7

26.3

25.5

Total Orthopaedics
$
3,408

$
3,216

6.0
 %
6.4
 %
7.7
 %
2.5
 %
3.7
 %
MedSurg:
 
 
 
 
 
 
 
Instruments
$
1,190

$
1,122

6.1
 %
6.3
 %
6.1
 %
5.9
 %
6.9
 %
Endoscopy
1,183

1,049

12.8

12.8

14.6

6.6

6.7

Medical
1,413

1,122

26.0

26.4

22.8

38.8

40.9

Sustainability
191

176

8.3

8.3

8.2

37.2

36.4

Total MedSurg
$
3,977

$
3,469

14.7
 %
14.9
 %
14.2
 %
16.5
 %
17.4
 %
Neurotechnology and Spine:
 
 
 
 
 
 
 
Neurotechnology
$
1,036

$
924

12.0
 %
12.6
 %
10.6
 %
14.7
 %
16.1
 %
Spine
552

559

(1.2
)
(0.9
)
(0.9
)
(2.3
)
(0.8
)
Total Neurotechnology and Spine
$
1,588

$
1,483

7.0
 %
7.5
 %
5.8
 %
9.7
 %
11.2
 %
Total
$
8,973

$
8,168

9.9
 %
10.2
 %
10.4
 %
8.5
 %
9.6
 %

4

NON-GAAP FINANCIAL MEASURES
We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; cost of sales excluding specified items; adjusted selling, general and administrative expenses; adjusted operating income; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share. We believe that these non-GAAP measures provide meaningful information to assist shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.
To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates and acquisitions that affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current and prior year results at the same foreign currency exchange rate excluding the impact of acquisitions. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, operating income, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures:
STRYKER CORPORATION
For the Three and Nine Months September 30
(Unaudited - Millions of Dollars, Except Per Share Amounts)
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Three Months 2017
Gross Profit
Selling, General & Administrative Expenses
Amortization of Intangible Assets
Operating Income
Net Earnings
Effective
Tax Rate
Diluted EPS
Reported
$
1,982

$
1,103

$
92

$
523

$
434

7.9
%
$
1.14

Acquisition and integration related charges: (a)
 
 
 
 
 
 
 
Inventory stepped-up to fair value
2

—

—

2

2

—

0.01

Other acquisition and integration related
—

(9
)
—

9

6

0.2

0.01

Amortization of purchased intangible assets
—

—

(92
)
92

66

2.7

0.18

Restructuring-related charges (b)
1

(35
)
—

36

27

0.7

0.07

Rejuvenate and other recall matters (c)
—

—

—

66

48

1.9

0.13

Legal matters (d)
—

—

—

—

(5
)
1.2

(0.02
)
Adjusted
$
1,985

$
1,059

$
—

$
728

$
578

14.6
%
$
1.52

Three Months 2016
Gross Profit
Selling, General & Administrative Expenses
Amortization of Intangible Assets
Operating Income
Net Earnings
Effective
Tax Rate
Diluted EPS
Reported
$
1,873

$
1,057

$
89

$
486

$
355

15.2
 %
$
0.94

Acquisition and integration related charges: (a)
 
 
 
 
 
 
 
Inventory stepped-up to fair value
2

—

—

2

1

0.2

—

Other acquisition and integration related
—

(47
)
—

47

44

(1.2
)
0.12

Amortization of purchased intangible assets
—

—

(89
)
89

62

2.7

0.16

Restructuring-related charges (b)
2

(23
)
—

25

20

0.1

0.05

Rejuvenate and other recall matters (c)
—

—

—

57

44

0.5

0.12

Adjusted
$
1,877

$
987

$
—

$
706

$
526

17.5
 %
$
1.39

Nine Months 2017
Gross Profit
Selling, General & Administrative Expenses
Amortization of Intangible Assets
Operating Income
Net Earnings
Effective
Tax Rate
Diluted EPS
Reported
$
5,934

$
3,335

$
275

$
1,578

$
1,269

10.3
%
$
3.34

Acquisition and integration related charges: (a)
 
 
 
 
 
 
 
Inventory stepped-up to fair value
2

—

—

2

2

—

0.01

Other acquisition and integration related
—

(27
)
—

27

20

0.2

0.05

Amortization of purchased intangible assets
—

—

(275
)
275

190

3.0

0.50

Restructuring-related charges (b)
12

(107
)
—

119

95

0.4

0.25

Rejuvenate and other recall matters (c)
—

—

—

164

123

1.1

0.33

Legal matters (d)
—

(30
)
—

30

20

0.4

0.05

Adjusted
$
5,948

$
3,171

$
—

$
2,195

$
1,719

15.4
%
$
4.53


5

Nine Months 2016
Gross Profit
Selling, General & Administrative Expenses
Amortization of Intangible Assets
Operating Income
Net Earnings
Effective
Tax Rate
Diluted EPS
Reported
$
5,409

$
3,044

$
230

$
1,505

$
1,137

14.7
 %
$
3.01

Acquisition and integration related charges: (a)
 
 
 
 
 
 
 
Inventory stepped-up to fair value
37

—

—

37

23

0.6

0.06

Other acquisition and integration related
—

(83
)
—

83

69

—

0.19

Amortization of purchased intangible assets
—

—

(230
)
230

160

2.2

0.42

Restructuring-related charges (b)
7

(60
)
—

67

54

0.1

0.14

Rejuvenate and other recall matters (c)
—

—

—

104

83

0.1

0.22

Legal matters (d)
—

12

—

(12
)
(7
)
(0.2
)
(0.02
)
Adjusted
$
5,453

$
2,913

$
—

$
2,014

$
1,519

17.5
 %
$
4.02

(a)
Charges represent certain acquisition and integration related costs associated with acquisitions.
(b)
Charges represent the cost associated with certain restructuring-related charges associated with workforce reductions and other restructuring-related activities.
(c)
Charges represent changes in our best estimate of the minimum end of the range of probable loss to resolve the Rejuvenate recall and other recall matters.
(d)
Amount represents gains or losses associated with legal settlements.
STRYKER CORPORATION
For the Three Months and Full Year December 31, 2017
Reconciliation of Expected Net Earnings Per Diluted Share to Expected Adjusted Net Earnings per Diluted Share
 
Three Months
 
Full Year
 
Low
High
 
Low
High
Expected - Reported
$
1.66

$
1.81

 
$
5.00

$
5.15

Acquisition and integration related charges
0.06

0.01

 
0.12

0.07

Amortization of purchased intangible assets
0.10

0.10

 
0.60

0.60

Restructuring-related charges
0.10

0.05

 
0.35

0.30

Rejuvenate and other recall matters
—

—

 
0.33

0.33

Legal matters
—

—

 
0.05

0.05

Expected - Adjusted
$
1.92

$
1.97

 
$
6.45

$
6.50


6
 GRAPHIC 3 strykerlogoa31.jpg begin 644 strykerlogoa31.jpg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end